Planned Maintenance: Some services may turn out to be unavailable from 15th January, 2026 to 16th January, 2026. We apologize for the inconvenience!

3OED image
Deposition Date 2010-08-12
Release Date 2011-05-11
Last Version Date 2024-10-16
Entry Detail
PDB ID:
3OED
Keywords:
Title:
The structure of the complex between complement receptor CR2 and its ligand complement fragment C3d
Method Details:
Experimental Method:
Resolution:
3.16 Å
R-Value Free:
0.25
R-Value Work:
0.18
Space Group:
H 3 2
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Complement C3
Gene (Uniprot):C3
Mutagens:C1010A
Chain IDs:A, C (auth: B)
Chain Length:310
Number of Molecules:2
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Complement receptor type 2
Gene (Uniprot):CR2
Chain IDs:B (auth: C), D
Chain Length:135
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
A crystal structure of the complex between human complement receptor 2 and its ligand C3d.
Science 332 608 611 (2011)
PMID: 21527715 DOI: 10.1126/science.1201954

Abstact

The interaction of complement receptor 2 (CR2)--which is present on B cells and follicular dendritic cells--with its antigen-bound ligand C3d results in an enhanced antibody response, thus providing an important link between the innate and adaptive immune systems. Although a cocrystal structure of a complex between C3d and the ligand-binding domains of CR2 has been published, several aspects of this structure, including the position in C3d of the binding interface, remained controversial because of disagreement with biochemical data. We now report a cocrystal structure of a CR2(SCR1-2):C3d complex at 3.2 angstrom resolution in which the interaction interfaces differ markedly from the previously published structure and are consistent with the biochemical data. It is likely that, in the previous structure, the interaction was influenced by the presence of zinc acetate additive in the crystallization buffer, leading to a nonphysiological complex. Detailed knowledge of the binding interface now at hand gives the potential to exploit the interaction in vaccine design or in therapeutics directed against autoreactive B cells.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback